Maternal Outcomes
0
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
ModernaCAMBRIDGE, MA
1 programStudy to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During PregnancyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2023
2024
2025
2026
ModernaStudy to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
Clinical Trials (1)
Total enrollment: 1,192 patients across 1 trials
NCT06369272ModernaStudy to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
Study to Assess Maternal and Infant Outcomes Following Exposure to SPIKEVAX During Pregnancy
Start: Mar 2023Est. completion: Oct 20231,192 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.